Nintedanib Teva

Nintedanib, the active ingredient in Nintedanib Teva, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is indicated for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and in combination regimens for non‑small cell lung cancer in adult patients under medical supervision and requires prescription.

GNH USA supplies Nintedanib Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established quality assurance processes and regulatory compliance across EU and other markets.

Nintedanib targets fibrotic lung disease pathways and certain cancer regimens.

Idiopathic pulmonary fibrosis (IPF): slows disease progression and reduces decline in lung function. Systemic sclerosis‑associated interstitial lung disease (SSc‑ILD): limits fibrotic remodeling and preserves respiratory capacity. Non‑small cell lung cancer (NSCLC) in combination therapy: enhances anti‑tumor activity when used with approved chemotherapeutic agents.

Adverse reactions may occur with any dose of Nintedanib.

Common Side Effects: - Diarrhea: frequent loose stools, often mild to moderate. - Nausea: sensation of unease or urge to vomit. - Vomiting: expulsion of stomach contents. - Abdominal pain: discomfort in the stomach area. - Decreased appetite: reduced desire to eat. - Elevated liver enzymes: increased ALT/AST levels.

Serious or Rare Side Effects: - Hepatic failure: severe liver injury requiring monitoring. - Gastrointestinal perforation: rare but potentially life‑threatening. - Severe bleeding: especially when combined with anticoagulants. - Arterial thromboembolism: clot formation in arteries. - Severe infections: opportunistic or bacterial infections. - Interstitial lung disease worsening: exacerbation of underlying lung condition.

Before initiating therapy, clinicians should assess baseline status and monitor patients regularly. - Monitor liver function: obtain baseline ALT/AST and repeat periodically. - Assess cardiovascular risk: evaluate for history of thromboembolic events. - Avoid in severe hepatic impairment: contraindicated when liver function is markedly compromised. - Use caution with bleeding disorders: consider risk of hemorrhage. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. - Store at ambient temperature below 25 °C: keep in the original pack, protect from moisture and light.

Nintedanib may interact with several drug classes; monitoring is advised.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase exposure. - Potent P‑gp inhibitors (e.g., verapamil): can raise plasma levels. - Anticoagulants (e.g., warfarin): heightened bleeding risk. - Antiplatelet agents (e.g., aspirin, clopidogrel): increased hemorrhagic potential.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Moderate P‑gp inhibitors (e.g., amiodarone): require dose observation. - Diuretics: monitor electrolytes and renal function. - Other tyrosine kinase inhibitors: potential additive toxicity.